Baby KJ — a CRISPR Therapy Built in Six Months for One Baby (2025)
The story
Skip to the verdict ↓An infant born with a lethal metabolic disorder became the first person ever treated with a gene-editing therapy designed and built for him alone — a bespoke CRISPR medicine created in about six months. The headlines reached for the words "miracle baby." The honest description is something rarer than a miracle: a designed medicine, engineered for one child by a team that knew exactly what it was doing, with its limits stated as plainly as its success.
KJ Muldoon — Kyle Muldoon Jr. — was born on August 1, 2024, in Philadelphia. Within a day, doctors found dangerously high levels of ammonia in his blood and diagnosed severe CPS1 deficiency, a urea-cycle disorder that affects roughly one baby in a million and is the deadliest of its kind. In this disorder the liver cannot clear a toxic byproduct of protein metabolism; if the ammonia is allowed to build, it reaches the brain and causes lasting damage. The usual tools — a strict low-protein diet, nitrogen-scavenging medications, and eventually a liver transplant that is risky in an infant — hold the danger at bay without removing its cause.
Two researchers had been asking whether medicine could go further: Rebecca Ahrens-Nicklas, a physician at Children's Hospital of Philadelphia, and Kiran Musunuru, of Penn Medicine, had been studying whether a gene-editing therapy could be built for a single patient. For KJ they designed one — a base-editing therapy, nicknamed "k-abe," aimed at the exact mutation on his paternal CPS1 gene and delivered to his liver inside lipid nanoparticles. From identifying his variant to a finished, FDA-cleared therapy took about six months, far faster than such work is usually imagined; the investigational-drug clearance came in roughly a week.
KJ received his first infusion in late February 2025, at about six months old, followed by two more doses in March and April. He had no serious side effects. He began tolerating more protein in his diet, needed less of his scavenger medication, and got through a rhinovirus infection without the ammonia crisis it would once have set off. He was discharged home in the spring of 2025.
His doctors have been careful with the word "cure." KJ will be followed for years; how long the edit will hold is not yet known; and he may still need a liver transplant later in childhood, though the therapy may push that day further off. The case was published in the New England Journal of Medicine on May 15, 2025.
It happened — and nature accounts for it.
Reviewer Notes
Miracles Jar weighs each claim two ways — how extraordinary it would be, and how strong the evidence is.
Assessed by Miracles Jar AI
Documented; fully explained (engineered medicine)
The verdict: "Documented; fully explained." This entry carries no supernatural claim at all. It marks a specific corner of the map — where the evidence is overwhelming and the miraculousness is essentially zero — with a twist that sets it apart even from the catalog's other engineered-medicine anchors.
Why the Miracle Meter sits at the floor
Nothing about this case is unexplained. Where a spontaneous remission leaves an open question — why did the tumor vanish? — KJ's recovery leaves none. The therapy was engineered to correct the exact letter of DNA that made him sick, and every step of it — design, manufacture, delivery, effect — is known and written down. Press coverage reached for "miracle baby," but that is the opposite of what this is: not an anomaly that defied explanation, but a wonder that was planned.
The honest limits
As with Towana Looney's pig kidney, the limits here are as documented as the success. KJ is not declared cured; the durability of the edit is unknown; a transplant may still lie ahead. Stating that plainly is what keeps the celebration honest — and it is the family's and the doctors' own framing, not a hedge imposed from outside.
Where it sits on the map
Anchor it beside the Geneva HIV-remission and Towana Looney cases: overwhelming evidence, floor-level miraculousness. It sits even a notch lower on the meter than those, because they were explained after the fact while KJ's therapy was designed from the start — the wonder was authored before it happened. If there is awe in this story, and there is, its name is science.
Evidence ledger — what the verdict rests on
Designed and administered by a named CHOP–Penn team led by Rebecca Ahrens-Nicklas and Kiran Musunuru, and reported in the peer-reviewed New England Journal of Medicine — a documented medical first, not a claim.
'Authentic' here means the event indisputably happened as reported; it carries no implication of the supernatural.
Objective clinical endpoints: after treatment KJ tolerated more dietary protein, needed less nitrogen-scavenger medication, and came through a viral infection without the ammonia crisis it would once have caused — then went home.
Nothing here is unexplained. The therapy was engineered base by base to correct the exact CPS1 mutation that made KJ sick, delivered to his liver in lipid nanoparticles, and a complete account of how it worked is known — this is the defining reason the Miracle Meter is at the floor.
It is not a declared cure. KJ's doctors are careful to say the edit's long-term durability is unknown and a liver transplant may still be needed later, even if delayed — the limits of the therapy are as documented as its success.
'Miracle baby' in the coverage is a figure of speech, not a claim — the scientists and the family described the case in terms of engineering, hope, and gratitude, never the supernatural.
What would raise the meter: Ruling out the remaining natural explanations — with records, follow-up, or base-rate math — would raise the meter.
What would lower it: A documented natural pathway for this outcome would move the meter down.
How this works
We keep two questions apart on purpose — so a thin record can’t make an impossible thing look proven, and a strong record can’t dress up an ordinary one as a miracle. First: Could nature explain it? (taking the account as true for the moment.) The question is whether nature could produce this at all — assuming, for the moment, the events are true as described. Second: is there real evidence it happened? A claim only stands out when both hold up — and we never call anything certain either way. How ratings work →
The natural explanation
The leading natural account for this case is skill, preparation & ordinary physics. Read what it explains — and where it stops.
Sources
Tagged by proximity to the event. Primary sources are direct or contemporaneous; tertiary are downstream retellings.
- 1.Primaryacademic
The primary peer-reviewed report of the world's first patient-specific in vivo CRISPR base-editing therapy, published online May 15, 2025. Establishes the mechanism (an adenine base editor delivered in lipid nanoparticles to the liver to correct KJ's paternal CPS1 Q335X variant), the ~6-month design-to-dose timeline, the three-dose course beginning late February 2025, and the early outcomes (no serious adverse events, increased dietary-protein tolerance, reduced nitrogen-scavenger medication). Cited from the journal record and CHOP/Penn's own account of the paper (direct nejm.org fetch is paywalled) — re-fetch at any future edit per citation-integrity.
- 2.Primaryother
Official institutional account (used as a primary institutional source, not a religious document). Fetch-verified for this entry: confirms the patient identifier KJ; severe CPS1 deficiency; lead physicians Rebecca Ahrens-Nicklas (CHOP) and Kiran Musunuru (Penn Medicine); a ~6-month timeline from variant to therapy; first dose in late February 2025 (age 6–7 months) with follow-up doses in March and April 2025; in vivo CRISPR base editing delivered via lipid nanoparticles to the liver; outcomes of no serious adverse effects, more dietary protein tolerated, reduced nitrogen-scavenger medication, and a rhinovirus weathered without ammonia buildup; and NEJM publication on May 15, 2025.
- 3.Secondarynews
Follow-up coverage corroborating the discharge home and the treatment course; situates KJ as the first patient to receive a personalized CRISPR therapy.
- 4.Secondarynews
"A bespoke CRISPR therapy suggests a blueprint for treating 'N-of-1' diseases", BioPharma Dive, 2025
Mainstream science-press corroboration framing the case as a proof-of-concept 'N-of-1' therapy and a possible template for other rare-disease patients — and noting, honestly, that durability and long-term follow-up remain open questions.
Cases like this
Nearest on the map — similar in how miraculous they’d be, and how strong the evidence is.